Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL

NCT06481228 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

82

Enrollment

OTHER

Sponsor class

Conditions

Philadelphia Positive Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia, Adult

Interventions

COMBINATION_PRODUCT: CAR-T cells
DRUG: Venetoclax
DRUG: Olverembatinib

Sponsor

Institute of Hematology & Blood Diseases Hospital, China